By admin 
The landscape of pediatric oncology is currently witnessing a transformative shift as researchers move beyond traditional cytotoxic treatments toward more targeted, biological interventions. At the forefront of this evolution is Dr. Hunter Jonus, PhD, a CureSearch Young Investigator based at Emory University’s Department of Pediatrics. Dr. Jonus is spearheading a pioneering research initiative focused on cellular immunotherapy, specifically targeting high-risk neuroblastoma—a disease that remains one of the most challenging and lethal malignancies in pediatric medicine. By utilizing a specialized subset of immune cells known as gamma delta ($gammadelta$) T cells, Dr. Jonus aims to bridge the gap between current survival rates and the ultimate goal of a definitive, non-toxic cure.
Understanding the Clinical Challenge of High-Risk Neuroblastoma
Neuroblastoma is a complex cancer that originates in the primordial crest cells of the sympathetic nervous system. It is recognized as the most common extracranial solid tumor found in infants and young children, accounting for approximately 7% to 10% of all childhood cancers and roughly 15% of all pediatric cancer deaths. The disease is characterized by its remarkable heterogeneity; while some cases in infants may undergo spontaneous regression, others are relentlessly aggressive and resistant to multi-modal therapy.
The clinical classification of neuroblastoma is divided into low, intermediate, and high-risk categories based on factors such as the child’s age at diagnosis, the tumor’s stage, and specific genetic markers, most notably the amplification of the MYCN oncogene. Approximately 50% of all neuroblastoma patients fall into the high-risk category. For these children, the standard of care is an intensive, multi-phase regimen that includes induction chemotherapy, surgical resection, high-dose chemotherapy followed by autologous stem cell transplantation, radiation therapy, and maintenance immunotherapy with anti-GD2 antibodies.
Despite this aggressive approach, the five-year survival rate for high-risk neuroblastoma hovers around 50%. The prognosis becomes significantly grimmer if the disease relapses or proves refractory to initial treatment. In cases of relapse, the overall survival rate plummets to less than 20%. Furthermore, those who do survive often face a lifetime of "late effects"—chronic health issues resulting from the toxicity of their treatment—including hearing loss, growth impairment, cardiac dysfunction, and a heightened risk of developing secondary malignancies later in life.
The Science of Gamma Delta T Cells in Oncology
The research conducted by Dr. Hunter Jonus focuses on a unique population of the immune system: gamma delta ($gammadelta$) T cells. Unlike the more common alpha beta ($alphabeta$) T cells that form the basis of most current T-cell therapies, $gammadelta$ T cells represent a smaller fraction of the total T-cell population but possess distinct advantages that make them ideal candidates for cancer immunotherapy.
$gammadelta$ T cells function as a bridge between the innate and adaptive immune systems. One of their most significant attributes is their ability to recognize and kill tumor cells in a Major Histocompatibility Complex (MHC)-independent manner. In simpler terms, while traditional T cells require the tumor to "present" specific markers via HLA molecules—which tumors often hide to evade the immune system—$gammadelta$ T cells can identify stressed or malignant cells directly. This makes them less likely to cause Graft-versus-Host Disease (GvHD), allowing for "off-the-shelf" applications where cells are harvested from healthy donors rather than the patient themselves.
Dr. Jonus’s methodology involves extracting these $gammadelta$ T cells from healthy donors and expanding them ex vivo (outside the body) using specialized protocols to increase their numbers and potency. These "super-charged" immune cells are then prepared for infusion into the patient, where they are expected to seek out and destroy neuroblastoma cells that have survived traditional chemotherapy.
Chronology of Clinical Implementation and Research Milestones
The journey from laboratory discovery to clinical application is a rigorous process. Dr. Jonus’s work has successfully navigated this path, leading to a landmark "first-in-child" clinical trial currently underway at Children’s Healthcare of Atlanta (CHOA).
- Pre-clinical Validation: Extensive laboratory testing demonstrated that donor-derived $gammadelta$ T cells could effectively target neuroblastoma cell lines without damaging healthy tissue.
- Protocol Development: Dr. Jonus and her team developed a sophisticated regimen that combines these $gammadelta$ T cells with existing chemoimmunotherapy. The goal is to use chemotherapy to debulk the tumor and "prime" the immune environment, making it more receptive to the infused T cells.
- Clinical Trial Launch: The trial at CHOA represents a critical milestone, offering a novel therapeutic option to children with relapsed or refractory high-risk neuroblastoma who have exhausted standard treatment options.
- The CureSearch Partnership: In 2023, Dr. Jonus was named a CureSearch Young Investigator. This prestigious grant provides the necessary funding and professional support to accelerate the translation of her research into clinical practice, ensuring that the project has the resources to move through the complex phases of human trials.
Supporting Data and the Need for Innovation
The necessity for Dr. Jonus’s research is underscored by historical data regarding neuroblastoma outcomes. Data from the Children’s Oncology Group (COG) indicates that while survival rates for many pediatric cancers have climbed above 80% or 90%, high-risk neuroblastoma has lagged behind.
The biological complexity of solid tumors like neuroblastoma presents a "hostile" tumor microenvironment (TME). Unlike liquid cancers such as leukemia, where T-cell therapies (like CAR-T) have seen massive success, solid tumors create physical and chemical barriers that prevent immune cells from penetrating the tumor. Furthermore, the TME often secretes immunosuppressive factors that "turn off" T cells upon arrival. Dr. Jonus’s future research specifically addresses these hurdles by engineering the $gammadelta$ T cells to be more resilient.
Enhancing Efficacy: CARs, Cytokines, and Checkpoint Blockade
While the current clinical trial is a major step forward, Dr. Jonus is already looking toward the next generation of cellular therapy. Her future research aims to maximize the functionality of $gammadelta$ T cells through three primary engineering strategies:
1. Chimeric Antigen Receptors (CARs)
By engineering $gammadelta$ T cells to express Chimeric Antigen Receptors (CARs), Dr. Jonus can give these cells a "GPS" system. These receptors are designed to bind specifically to antigens found on the surface of neuroblastoma cells (such as GD2 or B7-H3), ensuring that the T cells focus their attack directly on the malignancy with high precision.
2. Cytokine Secretion
One of the primary reasons T-cell therapies fail in solid tumors is a lack of persistence; the cells simply do not live long enough to finish the job. Dr. Jonus is exploring ways to engineer cells that secrete their own cytokines (growth factors). This "self-sustaining" mechanism would allow the $gammadelta$ T cells to survive and proliferate within the patient’s body for longer periods, providing a sustained anti-tumor effect.
3. Immune Checkpoint Blockade
Tumors often use "checkpoints" to trick the immune system into thinking they are normal cells. By integrating immune checkpoint blockade—either through genetic editing of the T cells or by combining the therapy with checkpoint inhibitor drugs—Dr. Jonus aims to remove the "brakes" from the immune system, allowing the $gammadelta$ T cells to function at full capacity regardless of the tumor’s attempts to suppress them.
Official Responses and Institutional Support
The selection of Dr. Jonus as a CureSearch Young Investigator has been met with significant enthusiasm within the academic and medical communities. CureSearch for Children’s Cancer, a national non-profit, focuses on funding research that has a high probability of reaching clinical trials quickly, filling the "gap" in federal funding for pediatric-specific oncology.
In a statement regarding her appointment and the future of the project, Dr. Jonus expressed her commitment to the patient population. “I am ecstatic to be selected as a CureSearch Young Investigator and for the opportunity to conduct this meaningful research with significant potential to impact patients’ lives,” she said. “I am hopeful for the future of $gammadelta$ T cell immunotherapy and its possibility to overcome barriers in the field of adoptive cell therapy so that more patients will be able to receive this powerful treatment approach.”
The Department of Pediatrics at Emory University and the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta have reinforced their support for Dr. Jonus, noting that her work represents a critical pillar in their mission to provide cutting-edge care for children with the most difficult-to-treat cancers.
Broader Impact and Implications for Pediatric Oncology
The implications of Dr. Jonus’s research extend far beyond neuroblastoma. If $gammadelta$ T cells can be successfully engineered to overcome the suppressive environments of solid tumors, this platform could theoretically be applied to other pediatric solid tumors, such as osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma.
Furthermore, the shift toward using healthy donor cells (allogeneic therapy) rather than the patient’s own cells (autologous therapy) could revolutionize the logistics of cancer treatment. Currently, CAR-T therapy requires a multi-week process of collecting, shipping, and modifying a patient’s cells, during which time a child’s disease may progress. An "off-the-shelf" $gammadelta$ T-cell product would allow for immediate treatment, a factor that is often life-saving in the context of aggressive relapses.
As Dr. Jonus continues her work at Emory University, the oncology community remains focused on the results of the ongoing trials at Children’s Healthcare of Atlanta. The goal is not merely to increase the number of survivors, but to ensure that those survivors can lead long, healthy lives free from the devastating side effects of traditional toxic therapies. Through the integration of advanced immunology, genetic engineering, and clinical dedication, the work of Dr. Hunter Jonus represents a significant step toward a new era in pediatric cancer care.